Cogent Biosciences, Inc. (COGT)
NASDAQ · Healthcare
As of Jul 20, 2026
Price history
Key statistics
- Market cap
- $6.84B
- P/E ratio
- —
- EPS
- —
- Volume
- 1,160,988
- 52-week high
- —
- 52-week low
- —
- Open
- $39.45
- Day high
- $39.85
- Day low
- $38.04
Financial highlights
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| 2025 | — | -$328.94M | -$2.16 |
| 2024 | — | -$255.86M | -$1.94 |
| 2023 | — | -$192.41M | -$1.94 |
| 2022 | — | -$140.24M | -$1.73 |
| 2021 | — | -$72.27M | -$1.87 |
About Cogent Biosciences, Inc.
Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies. The company's primary therapeutic candidate is CGT9486, a selective tyrosine kinase inhibitor engineered to block the KIT D816V mutation, a key driver of systemic mastocytosis, along with other KIT exon 17 mutations observed in individuals suffering from advanced gastrointestinal stromal tumors (GIST). Furthermore, Cogent holds a licensing pact with Plexxikon Inc., granting it rights for the investigation, advancement, and marketing of bezuclastinib. Previously known as Unum Therapeutics Inc., the company adopted its current name, Cogent Biosciences, Inc., in October 2020. Established in 2014, Cogent Biosciences is headquartered in Cambridge, Massachusetts.
- CEO
- Andrew R. Robbins
- Employees
- 258
- Country
- US
- IPO date
- Mar 29, 2018
Similar stocks
Other Healthcare companies
Frequently asked questions
- What is Cogent Biosciences, Inc.'s stock price today?
- COGT is trading at $38.30 as of Jul 20, 2026.
- What is Cogent Biosciences, Inc.'s market cap?
- Cogent Biosciences, Inc. (COGT) has a market capitalization of $6.84B.
- Does Cogent Biosciences, Inc. pay a dividend?
- Cogent Biosciences, Inc. did not pay a dividend in its most recent reported fiscal year.
- What sector is Cogent Biosciences, Inc. in?
- Cogent Biosciences, Inc. operates in the Healthcare sector.